EUCTR2017-002407-10-GB进行中（未招募）1 期
A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery. - BARI-OPTIMISE Version 1
niversity College London0 个研究点目标入组 70 人开始时间: 2018年1月30日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients, 1 year or more after primary RYGB or primary SG, with poor weight-loss (<20% WL) that is not caused by either a surgical or psychological problem.
- •2.Adults, 18-64 years inclusive.
- •3.Suboptimal nutrient-stimulated GLP-1 response assessed by a meal test. Suboptimal active GLP-1 response is defined as a =2-fold increase in active GLP-1 circulating levels between time 0 and time 30 minutes.
- •4.Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control, abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.
- •5.Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for trial treatment. NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
- •6.=5 % variation in body weight over preceding 3 months.
- •7.Fluent in English and able to understand and complete questionnaires.
- •8.Willing and able to provide written informed consent and comply with the trial protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Had a surgical procedure other than gastric bypass and sleeve gastrectomy,or revision bariatric surgery of any operation type.
- •2.Pregnant or lactating mothers.
- •3.Participation in other clinical intervention trial.
- •4.Lifetime history of suicidal behaviour or severe depression assessed by direct questioning.
- •5.Clinically significant medical abnormalities (e.g., unstable hypertension, clinically significant ECG abnormalities, liver cirrhosis, AST or ALT > 3x the upper normal limit).
- •6.Heart rate = 100 beats/minute at screening on two separate measurements.
- •7.Uncontrolled hypertension (systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg).
- •8.Renal impairment (estimated glomerular infiltration rate (eGFR <30 ml/min 1.73 m2)
- •9.Known or suspected hypersensitivity to liraglutide 3.0 mg and placebo or any of the excipients involved in their formulation.
- •10.Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
- •11.Personal history of pancreatitis.
- •12.Uncontrolled hypothyroidism or hyperthyroidism.
- •13.History of stroke, unstable angina, acute coronary syndrome, congestive heart failure New York Heart Association class III-IV within the preceding 12 months.
- •14.History of arrhythmias.
- •15.Inflammatory bowel disease.
- •16.Diabetic gastroparesis.
- •17.Concomitant GLP-1 receptor agonist usage.
- •18.Concomitant usage of medications that cause weight gain or weight loss.
- •19.Concomitant usage of DPPIV-inhibitors.
- •20.Insulin usage.
研究者
相似试验
已完成
2 期
Evaluation of the MonaLisa Touch procedure in the treatment of postmenopausal vulvovavaginal symptomsACTRN12616001403426GRACE Unit - School of Women's and Children's Health, UNSW Sydney, Australia94
已完成
不适用
A randomised, double-blinded, placebo-controlled trial using cardiovascular magnetic resonance (CMR) scanning to assess remodelling and regression of fibrosis in cardiomyopathy with eplerenoneCardiomyopathyISRCTN23314770Record Provided by the NHSTCT Register - 2007 Update - Department of Health140
进行中（未招募）
1 期
A trial that evaluates the effect of empagliflozin on oxidative stress in patients with type 2 diabetesType 2 diabetesMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2016-000370-38-DKRigshospitalet, Klinisk Farmakologisk Afd. Q764235
已完成
不适用
Oral magnesium for relief in pregnancy-induced leg crampsPregnant women with leg crampsPregnancy and ChildbirthISRCTN03989660Chulalongkorn University (Thailand)86
进行中（未招募）
1 期
Effect of brodalumab compared to placebo on vascular inflammation in moderate-to-severe psoriasisEUCTR2017-003697-14-DKAarhus University Hospital50